Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYCRRT: 68Ga-NY104 Guided RT in ccRCC
NCT06613269Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NYM005 in clear cell renal cell carcinoma (ccRCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression free survival 2 at 4 years. Started Mar 2024; status: recruiting.
02
Drugs
68Ga-NYM005
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06613269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613269.